Marshall Ladd, DO
Pain Medicine · Omaha, NENPI 1619363199
Payments from drug & device makers
What this record shows
This record is dominated by grants: $5,625 of the $7,125 with a category attached, or 78.9%. Medtronic accounts for 81.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $5,666 and has fallen 95.3% since, to $264 in 2025.
Across 17 payments — averaging $419.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Nevro Corp.$658
- Stimwave Technologies Incorporated$282
- Saluda Medical Americas, Inc.$148
- Averitas Pharma Inc.$122
- Boston Scientific$88
- plus $57 from 3 others
What the payments were for
- Grants$5,62579%
- Travel & lodging$1893%
- Food & beverage$1,31118%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 3 | $5,770 |
| Nevro Corp. | 6 | $658 |
| Stimwave Technologies Incorporated | 2 | $282 |
| Saluda Medical Americas, Inc. | 1 | $148 |
| Averitas Pharma Inc. | 1 | $122 |
| Boston Scientific | 1 | $88 |
| Edwards Lifesciences | 1 | $26 |
| Nalu Medical, Inc. | 1 | $19 |
| SPR Therapeutics, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,125 in reported general payments places this provider in the 55th percentile of 31 pain medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 101 | $1,746 |
| Pregabalin | 135 | $1,621 |
| Duloxetine Hcl | 87 | $1,383 |
| Naltrexone Hcl | 22 | $1,064 |
| Nortriptyline Hcl | 75 | $968 |
| Celecoxib | 28 | $514 |
| Meloxicam | 105 | $499 |
| Tizanidine Hcl | 42 | $348 |
| Nabumetone | 23 | $301 |
| Topiramate | 37 | $137 |
| Methocarbamol | 13 | $124 |
| Cyclobenzaprine Hcl | 17 | $102 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Omaha
- Matthew StottleOmaha$14K
- Katie BerkyOmaha$12K
- Tyrus SoaresOmaha$8K
- Apollo StackOmaha$8K
- Jess RolandOmaha$8K
- James DevneyOmaha$5K
- Peter PiperisOmaha$4K
- Dan NichollsOmaha$3K
- Ernesto PadronOmaha$3K
- Christopher CriscuoloOmaha$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.